SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant attention as investors react to a strategic acquisition and persistent rumors of potential partnerships, with community sentiment fueled by the stock's high volatility and strong correlation to Bitcoin's price action. While some traders are focused on a potential short squeeze or a broader institutional re-rating, others remain cautious, debating the long-term impact of share dilution and the company's ability to execute on its pivot toward stablecoin settlement and institutional infrastructure.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors position themselves for a significant PDUFA date on May 31, 2026, for its lead ADHD candidate, CTx-1301. The community is actively discussing the stock's low float, recent financing activities, and the anticipated news regarding U.S. patent approvals for its Precision Timed Release technology.

FIS Trust - FIS Christian Stock Shares of beneficial interest

SHP ETF Trust - FIS Biblically Responsible Risk Managed ETF

Investors are actively debating the intersection of personal faith and portfolio management, with many sharing scripture and reflections on ethical investing within the PRAY ETF community. While some participants are discussing the fund's alignment with their values, others are using the platform as a space to share personal motivations for market participation and conservative lifestyle principles.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant market volatility as investors weigh mixed interim Phase 2 clinical data for its cystic fibrosis candidate, ARCT-032, against the company's solid cash position and broader pipeline progress. While the community is actively debating the significance of observed mucus reduction versus the lack of meaningful lung function improvement, many are scrutinizing the stock's sharp sell-off as a potential overreaction to early-stage trial hurdles.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as investors aggressively hedge against heightened geopolitical risks, including escalating tensions with Iran and uncertainty surrounding new trade tariff policies. The community is actively debating the volatility ETF's structural decay, with many traders using it as a tactical tool to capitalize on daily market swings and anticipated macro-economic shocks.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is trending as traders attempt to capitalize on heightened volatility and geopolitical tensions surrounding the Strait of Hormuz, with many in the community debating whether to treat the stock as a tactical swing trade or a long-term position. Discussion is dominated by concerns over the ETF's decay and daily rebalancing, alongside conflicting views on whether supply disruptions will lead to a sustained price spike or a swift reversal once conflict conditions stabilize.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is gaining significant momentum as investors pivot toward its long-term potential as an AI and energy-infrastructure company rather than just an EV manufacturer. The community is actively discussing the company's recent expansion of its battery-swapping network and its strategic move into self-developed AI chips, with many looking toward upcoming vehicle delivery milestones as a key catalyst to drive the share price through current resistance levels.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently facing heightened volatility as investors weigh the company's long-term potential as a provider of nuclear energy for AI data centers against near-term concerns regarding its pre-revenue status and the broader regulatory landscape. The community is actively debating the stock's future, with some pointing to strategic partnerships and licensing milestones as catalysts for growth, while others remain skeptical due to insider selling, limited commercial output, and a heavy reliance on future policy developments.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as investors react to reports of a significant new share buyback program and record annual profit guidance ahead of the company's highly anticipated earnings release. Community sentiment remains overwhelmingly bullish, with long-term shareholders highlighting the company's successful turnaround, robust defense order backlogs, and emerging catalysts in SMR and narrow-body engine development.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by regional conflict in the Middle East and concerns over the stability of the Strait of Hormuz. The community is actively debating the impact of potential supply disruptions against the backdrop of broader economic uncertainty, with traders sharply divided between bullish expectations for continued energy price spikes and bearish concerns regarding aggressive market manipulation and speculative bubbles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen, which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. The company also develops and invests in stem cell and medical technology. Diamyd Medical was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

DYMDF
Diamyd Medical AB - Ordinary Shares - Class B

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DYMDF News

DYMDFDiamyd Medical AB - Ordinary Shares - Class B